43 Recruiting Studies Using Enfortumab Vedotin
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Enfortumab Vedotin
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
📍 Arizona Oncology — Tucson, Arizona
Locally Advanced or Metastatic Malignant Solid Tumors
View Study & Checklist ➔Enfortumab Vedotin in Previously Treated Locally Advanced or Metastatic Pancreatic Cancer (EPIC)
📍 University of Kansas Cancer Center — Kansas City, Kansas
Pancreatic Ductal Adenocarcinoma
View Study & Checklist ➔Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma
📍 Fox Chase Cancer Center - Philadelphia — Philadelphia, Pennsylvania
Urothelial Carcinoma
View Study & Checklist ➔Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
📍 Research Site — Orange, California
Muscle Invasive Bladder Cancer
View Study & Checklist ➔Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
📍 Ironwood Cancer & Research Centers - Chandler — Chandler, Arizona
Urothelial Cancer
View Study & Checklist ➔A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
📍 University of California San Francisco HDFCCC ( Site 4044) — San Francisco, California
Metastatic Urothelial Carcinoma
View Study & Checklist ➔A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
Urothelial Carcinoma
View Study & Checklist ➔Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy
📍 Los Angeles General Medical Center — Los Angeles, California
Locally Advanced Bladder Urothelial Carcinoma
View Study & Checklist ➔A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
📍 UCLA Hematology/Oncology - Westwood (Building 200 Suite 140)-Department of Urology/Institute of Uro ( Site 0104) — Los Angeles, California
Bladder Cancer
View Study & Checklist ➔Enfortumab Vedotin as Monotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer
📍 Huntsman Cancer Institute — Salt Lake City, Utah
Metastatic Castration-resistant Prostate Cancer
View Study & Checklist ➔Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
📍 Mayo Clinic in Arizona - Phoenix ( Site 0043) — Phoenix, Arizona
Bladder Cancer
View Study & Checklist ➔Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
📍 University of South Alabama, Mitchell Cancer Institute ( Site 1582) — Mobile, Alabama
Urinary Bladder Cancer, Muscle-invasive
View Study & Checklist ➔The Impact of Time-of-day Administration of EV/P on Objective Response Rate in Adults With Advanced Bladder Cancer
📍 BC Cancer - Abbotsford — Abbotsford British Columbia, British Columbia
Advanced Bladder Cancer
View Study & Checklist ➔Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer
📍 City of Hope — Duarte, California
Advanced Urothelial Cancer
View Study & Checklist ➔A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
📍 Arkansas Urology Associates — Little Rock, Arkansas
Muscle-invasive Bladder Cancer
View Study & Checklist ➔Study of EV for Recurrent Endometrial Carcinoma
📍 Froedtert Memorial Lutheran Hospital — Milwaukee, Wisconsin
Endometrial Cancer
View Study & Checklist ➔Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer
📍 UT Southwestern Medical Center — Dallas, Texas
Bladder Cancer
View Study & Checklist ➔Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Metastatic Bladder Urothelial Carcinoma
View Study & Checklist ➔Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
📍 University of California, San Francisco — San Francisco, California
Bladder Cancer
View Study & Checklist ➔Cabozantinib in Combination With Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
📍 Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation
View Study & Checklist ➔Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology
📍 Grady Health System — Atlanta, Georgia
Bladder Squamous Cell Carcinoma
View Study & Checklist ➔Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Upper Tract Urothelial Cancer
📍 University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
Urothelial Carcinoma
View Study & Checklist ➔Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
📍 Highlands Oncology Group, PA — Fayetteville, Arkansas
Urothelial Cancer
View Study & Checklist ➔A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
📍 Memorial Sloan Kettering Basking Ridge (All Protocol Activities) — Basking Ridge, New Jersey
Adenoid Cystic Carcinoma
View Study & Checklist ➔Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
📍 Samsun Clinic - Ridley-Tree Cancer Center — Santa Barbara, California
Urothelial Cancer
View Study & Checklist ➔Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Locally Advanced Bladder Urothelial Carcinoma
View Study & Checklist ➔Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis
📍 Mayo Clinic Hospital in Arizona — Phoenix, Arizona
Metastatic Penile Squamous Cell Carcinoma
View Study & Checklist ➔Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line Metastatic Urothelial Carcinoma
📍 Fox Chase Cancer Center - Philadelphia — Philadelphia, Pennsylvania
Metastatic Urothelial Carcinoma
View Study & Checklist ➔Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
📍 Moffitt Cancer Center — Tampa, Florida
Metastatic Colorectal Cancer
View Study & Checklist ➔An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
📍 Research Site — Hot Springs, Arkansas
High-risk Muscle Invasive Urothelial Carcinoma
View Study & Checklist ➔Renal Retention in High Grade Upper Tract Urothelial Cancer
📍 Johns Hopkins University: Sibley Memorial Hospital — Washington D.C., District of Columbia
High Grade Urothelial Carcinoma
View Study & Checklist ➔Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
📍 Sarcoma Oncology Center — Santa Monica, California
Muscle-Invasive Bladder Carcinoma
View Study & Checklist ➔Sacituzumab Govitecan Plus EV in Metastatic UC
📍 Dana Farber Cancer Institute — Boston, Massachusetts
Urothelial Cancer
View Study & Checklist ➔Enfortumab Vedotin With or Without Pembrolizumab in Rare Genitourinary Tumors (E-VIRTUE)
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Adenocarcinoma of the Bladder
View Study & Checklist ➔Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
📍 The University of Arizona Cancer Center-North Campus — Tucson, Arizona
Metastatic Urothelial Cancer
View Study & Checklist ➔Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
📍 Baptist Alliance MCI — Miami, Florida
Urothelial Carcinoma
View Study & Checklist ➔Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer
📍 UCLA / Jonsson Comprehensive Cancer Center — Los Angeles, California
Renal Pelvis and Ureter Urothelial Carcinoma
View Study & Checklist ➔Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
📍 MD Anderson Cancer Center — Houston, Texas
Advanced Bladder Cancer
View Study & Checklist ➔FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
📍 University of Arizona - Cancer Center — Tucson, Arizona
Urinary Bladder Neoplasms
View Study & Checklist ➔Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
📍 City of Hope — Duarte, California
Muscle Invasive Bladder Urothelial Carcinoma
View Study & Checklist ➔A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
📍 John Theurer Cancer Center at Hackensack University Medical Center — Hackensack, New Jersey
Locally Advanced or Metastatic Malignant Solid Tumors
View Study & Checklist ➔Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
📍 City of Hope Comprehensive Cancer Center — Duarte, California
Advanced Malignant Solid Neoplasm
View Study & Checklist ➔Enfortumab Vedotin and Pembrolizumab With Cystectomy and/or Ureterectomy for Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Locally Advanced Bladder Urothelial Carcinoma
View Study & Checklist ➔